NewcelX Ltd.
Business
NewcelX Ltd. is a clinical-stage biopharmaceutical company developing therapies for rare and complex central nervous system (CNS) disorders. It offers lead product candidates Quilience and Nolazol—both mazindol-based, once-daily controlled‑release formulations—and a discovery pipeline including NLS‑4 and a Dual Orexin Receptor Agonist platform licensed from Aexon. Its key business segments include small‑molecule CNS therapeutics and, following a merger agreement, a cell‑therapy franchise via Kadimastem. NewcelX distributes and develops products through clinical trials, named‑patient/compassionate‑use programs, regulatory filings and third‑party manufacturing and licensing arrangements across the U.S., Europe and other international markets.
Summary from filing dated 2025-05-16
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-8.30M |
| Total assets | $11.45M |
| Total liabilities | $4.20M |
| Stockholders' equity | $7.25M |
| Operating cash flow | $-2.77M |